Strategic Partnership Ametris is actively forming and expanding collaborations, including a strategic partnership with Kayentis to integrate eCOA and wearable technology in trials and notable affiliations with Novo Nordisk, Roche, Eli Lilly, Novo Nordisk, and AstraZeneca through DECODE working groups, signaling strong potential for joint deployments and co-sell opportunities with large pharma.

Acquisition Signal Recent news indicates Signant Health is planning to acquire Ametris, suggesting a potential exit, integration, or channel shift that could open new routes to market, distribution channels, or customer access through a consolidated platform.

Neuromuscular Focus Ametris launched digital measures for tracking functional capacity to advance neuromuscular disease research, presenting a sales angle to biopharma and CROs pursuing neurological indications and real-world evidence collection in tightly regulated therapeutic areas.

DHT and Wearables The end-to-end digital health tremor combines wearable technologies, regulatory-aligned analytics, and expert consultation, creating cross-sell opportunities with EHR integrations, data management platforms, and analytics services for sponsors seeking end-to-end digital trial solutions.

Global Pharma Engagement Active partnerships and expansion with industry peers and major pharma players through DECODE groups and upcoming collaborations imply readiness for multi-region deployments, enabling a sales narrative around scalable digital health programs across diverse trials and geographies.